SCHEDULE: Vanguard Discloses 5.21% Stake in Apogee Therapeutics

The Vanguard Group has reported a 5.21% beneficial ownership stake in Apogee Therapeutics Inc. common stock as of December 31, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 2,857,824 shares of Apogee Therapeutics Inc. common stock.
• This ownership represents 5.21% of the company's outstanding common stock.
• Vanguard holds shared voting power over 374,247 shares and shared dispositive power over all 2,857,824 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Apogee Therapeutics Inc.
• An internal realignment at The Vanguard Group, Inc. on January 12, 2026, will result in certain subsidiaries reporting beneficial ownership separately in future filings.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the disclosure of a significant passive stake by The Vanguard Group typically signals institutional confidence in the issuer, Apogee Therapeutics Inc.

Positives

• Significant institutional investment from The Vanguard Group, a major asset manager, signals confidence in Apogee Therapeutics Inc.
• Vanguard's passive investment approach suggests a long-term holding strategy, which can provide stability to the stock.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by a major institutional investor like The Vanguard Group often provides a positive signal to the market, indicating that the company has met the investment criteria of a large, diversified fund manager. This can enhance investor confidence and potentially attract further institutional interest, especially for a company like Apogee Therapeutics Inc. in the biotechnology or pharmaceutical sector, where long-term capital is crucial.

Stakeholder Impact

• Shareholders: Increased institutional ownership may lead to greater stock stability and potentially attract more investors, validating the company's investment thesis.

Key Dates

Recommendation

The disclosure of a significant passive stake by The Vanguard Group is generally a positive indicator, suggesting institutional confidence. However, as a Schedule 13G filing, it does not provide operational or financial performance details of Apogee Therapeutics Inc. to warrant a 'buy' recommendation. Investors should 'hold' and await further fundamental information from the company's own financial reports to make a more informed decision, while acknowledging the positive signal from Vanguard's investment.

Keywords

Apogee Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Adviser, APGE